Learning Objectives

At the end of this educational activity, participants should be able to:

• Recognize the latest systemic therapies for renal cell carcinoma
  
• Combine immune checkpoint inhibitors and targeted agents
  
• Identify and select patients who would benefit from these therapeutic approaches
  
• Monitor treatment response and mitigate adverse events

This programme is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 1 European CME credit (ECMEC®) for every hour (60 minutes) of use, provided that the users have completed a module and have passed the relevant assessment.